SkinBioTherapeutics shortlisted for Biotech and Money 2017 Awards

SkinBioTherapeutics shortlisted for Biotech and Money 2017 Awards

SkinBioTherapeutics plc, a life science company focused on skin health, has been nominated as a finalist in the Life Science IPO of the Year category of the Biotech and Money 2017 Awards....

15th June, 2017 Read More

SkinBioTherapeutics presenting at Made in the UK

SkinBioTherapeutics presenting at Made in the UK

SkinBioTherapeutics will be presenting at this years Made in the UK awards....

12th June, 2017 Read More

Presentation at the Artic University of Norway

Presentation at the Artic University of Norway

Dr O'Neill is speaking at the Artic University of Norway 2nd June 2017...

1st June, 2017 Read More

Extension of Research Contract 23 May 2017

Extension of Research Contract 23 May 2017

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company's Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract exte...

23rd May, 2017 Read More

First Day of Dealings on AIM

First Day of Dealings on AIM

5 April 2017 - Manchester, UK - SkinBioTherapeutics plc (AIM: SBTX, the 'Company'), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM at 08:00 today under the ticker code SBTX and the ISIN number: GB00BF33H870....

5th April, 2017 Read More

Board Announcement

Board Announcement

The Board of SkinBioTherapeutics has noted the possible confusion that could arise with regard to the Tickers of SkinBioTherapeutics plc ('SkinBio') and Integumen plc ('Integumen'). It should be noted that the TICKER of SkinBio is 'SBTX' and the TICKER of Integumen is 'SKIN'. Both companies ...

3rd April, 2017 Read More
investors logo